NCT02895672View on ClinicalTrials.gov

GLP-1/Basal Insulin Combination Therapy

CompletedOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

GLP-1 therapy

The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.

All Listed Sponsors

lead

Albany College of Pharmacy and Health Sciences

OTHER

NCT02895672 - GLP-1/Basal Insulin Combination Therapy | Biotech Hunter | Biotech Hunter